CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Chilcott UK Ltd (ADR) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Chilcott UK Ltd (ADR)
Old Belfast Road, Millbrook
Phone: +44 2828267222p:+44 2828267222 LARNE CO ANTRIM BT40 1EJ, BT40 2SH  United Kingdom
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Chilcott UK Ltd is an international pharmaceutical company focused principally on the therapeutic areas of women's healthcare and dermatology. The Company develops, manufactures, supplies and markets branded prescription pharmaceutical products in the United States, United Kingdom and Ireland. Galen develops and markets products for a number of segments in the women's healthcare therapeutic area, including oral contraceptives, hormone therapy and premenstrual dysphoric disorder. Its principal products are Ovcon 35 and Ovcon 50, Estrostep, Loestrin/Minestrin, femhrt, Estrace tablets, Estrace cream, Femring/Menoring and Sarafem. The Company's line of dermatology products includes Doryx and Dovonex. Galen also has a pipeline of products in development principally for the United States market, including products utilizing the vaginal ring drug delivery technology.
(Source: 20-F)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20049/30/2003Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President- Pharmaceuticals W. CarltonReichel 45
Executive Vice President- Corporate Development, General Counsel, Secretary Anthony D.Bruno 47
Senior Vice President-Finance William J.Poll 51
8 additional Officers and Directors records available in full report.

General Information
Shareholders: 576
Stock Exchange: OTC
Email Address: info@galenplc.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023